In a 24-year-old female with a 4-year history of PANS receiving IVIG who presents with fatigue and brain fog, normal CBC and iron studies, and euthyroid thyroid function tests but intermittent elevations of anti‑thyroperoxidase and anti‑thyroglobulin antibodies, what follow‑up laboratory testing and management steps are recommended?

Management Recommendation

Continue monitoring thyroid antibodies every 3-6 months without initiating levothyroxine therapy, while recognizing that IVIG treatment is likely causing transient elevations in thyroglobulin antibodies that do not reflect true thyroid disease progression.

Key Clinical Context

Your patient's thyroid function tests remain consistently euthyroid (TSH 0.827-2.73 mIU/L, Free T4 1.0-1.2 ng/dL, Free T3 3.0-3.5 pg/mL), which is the critical determinant here. The fluctuating antibody levels—particularly the spike in thyroglobulin antibodies to 124 IU/ml and TPO antibodies to 83 IU/ml—are occurring in the context of ongoing IVIG therapy, which is highly relevant.

The IVIG-Antibody Connection

IVIG preparations contain thyroid autoantibodies from pooled donor plasma 1, 2, 3. This creates a diagnostic pitfall:

• Commercially available thyroglobulin and TPO antibody assays detect these exogenous antibodies from IVIG, not just the patient's endogenous antibodies 2, 3
• Antibody levels are highest soon after IVIG infusion and decline over 1-2 months 2
• Your patient's antibody fluctuations (rising from 16-17 to 124 IU/ml for thyroglobulin Ab, then falling back to 44 IU/ml) follow this exact pattern of transient elevation 2

This means the antibody elevations may be artifactual rather than representing true disease progression.

Thyroid Treatment Decision Framework

Based on established guidelines for subclinical hypothyroidism 4, 5:

Do NOT treat with levothyroxine because:

1. TSH remains <4.5 mIU/L: The most recent TSH is 0.827 mIU/L, well within normal range 4
2. No biochemical hypothyroidism: Free T4 and T3 are normal 4, 5
3. Guideline threshold not met: Treatment is only reasonable when TSH >10 mIU/L, and even for TSH 4.5-10 mIU/L, routine treatment is not recommended 4
4. Antibodies alone don't mandate treatment: While TPO antibodies predict progression (4.3% per year with positive antibodies vs 2.6% without), treatment is based on TSH elevation, not antibody presence 5

The fatigue and brain fog are NOT attributable to thyroid dysfunction:

• These symptoms are common in PANS itself 6, 7
• With normal thyroid function tests, levothyroxine would provide no benefit beyond placebo 4
• The evidence for symptom improvement with treatment of subclinical hypothyroidism (TSH 4.5-10 mIU/L) is already weak; with TSH <4.5 mIU/L, there is no basis for expecting benefit 4

Recommended Follow-Up Strategy

Thyroid Monitoring:

1. Repeat thyroid function tests (TSH, Free T4) every 6-12 months 4
2. Time antibody testing strategically: If checking antibodies, obtain samples >6-8 weeks after IVIG infusion to minimize interference from exogenous antibodies 2
3. Watch for TSH elevation: Only initiate levothyroxine if TSH rises above 10 mIU/L, or consider a trial if TSH 4.5-10 mIU/L with clear hypothyroid symptoms 4

Address the Actual Symptoms:

The fatigue and brain fog warrant evaluation for:

• PANS disease activity: These are core PANS symptoms that may respond to optimization of immunomodulatory therapy 6, 7
• IVIG-related effects: Ensure adequate hydration and monitor for IVIG side effects including headache, which can contribute to cognitive symptoms 1
• Sleep disorders: Common in PANS and neuropsychiatric conditions
• Vitamin D, B12: Though you've checked iron, these are worth evaluating
• Depression/anxiety: Integral to PANS presentation

Critical Pitfalls to Avoid

1. Do not treat antibodies alone: The presence of thyroid antibodies without TSH elevation does not warrant levothyroxine 4, 5
2. Do not misinterpret IVIG-induced antibody elevations: Rising antibodies in a patient on IVIG may reflect passive antibody transfer, not disease progression 2, 3
3. Do not attribute all symptoms to thyroid: With normal thyroid function, the neuropsychiatric symptoms are more likely related to PANS itself 6, 7
4. Do not over-test antibodies: Frequent antibody monitoring adds no clinical value when thyroid function is normal and may cause unnecessary alarm 2, 3

Special Consideration for PANS

Recent evidence shows IVIG improves PANS symptoms through reduction in pro-inflammatory monocytes 6. The patient's "some improvement" over 8 months suggests partial response. If symptoms persist despite continued IVIG, consider:

• Optimizing IVIG dosing/frequency
• Evaluating for ongoing infectious triggers
• Adding other immunomodulatory approaches per PANS treatment guidelines

The thyroid is not the problem here—focus on optimizing PANS management while monitoring thyroid function conservatively.